Given that sPD-L1 in peripheral blood is attributed to PD-L1-positive tumor cells and TAMs, It should be noted that in operable NSCLC patients with high plasma sPD-L1 levels, postoperative prognosis differs depending on its source of sPD-L1, tumor cells or TAMs. This evidence concerns the gene SPDL1 and neoplasm.